{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:26:51Z","timestamp":1776425211954,"version":"3.51.2"},"reference-count":20,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openrespiratorymedicinejournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TORMJ"],"published-print":{"date-parts":[[2026,4,17]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction\/background<\/jats:title>\n                    <jats:p>The prognosis of patients with Pulmonary Hypertension (PAH) associated with the intake of anorexigens and amphetamines has not been clearly defined. Published data are suboptimal due to a scarcity of corroborating hemodynamic information. There are reports of worse, the same, and better prognoses compared to patients with idiopathic pulmonary arterial hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Our experience with three patients who had PAH, a history of amphetamine-like drug use, and comorbidities is described, and the pertinent literature is summarized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Three patients with PAH and a history of amphetamine-like drug use demonstrated markedly improved hemodynamics at follow-up catheterizations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0118743064473701260415041740","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:32:17Z","timestamp":1776421937000},"update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Marked Improvement in Pulmonary Arterial Hypertension in 3 Patients with a History of Amphetamine-like Drug use and Comorbidities"],"prefix":"10.2174","volume":"20","author":[{"given":"Emily","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7092-5784","authenticated-orcid":true,"given":"Abraham","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/hrt.70.6.537","volume":"70","author":"Brenot F.","year":"1993","unstructured":"Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. \n          Primary pulmonary hypertension and fenfluramine use. \n          Heart  \n          1993; \n          70\n          (6)\n          : 537-41.","journal-title":"Heart"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1378\/chest.130.6.1657","volume":"130","author":"Chin K.M.","year":"2006","unstructured":"Chin KM, Channick RN, Rubin LJ. \n          Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? \n          Chest  \n          2006; \n          130\n          (6)\n          : 1657-63.","journal-title":"Chest"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJM199608293350901","volume":"335","author":"Abenhaim L.","year":"1996","unstructured":"Abenhaim L, Moride Y, Brenot F, et al. \n          Appetite-suppressant drugs and the risk of primary pulmonary hypertension. \n          N Engl J Med  \n          1996; \n          335\n          (9)\n          : 609-16.","journal-title":"N. Engl. J. Med."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.amjcard.2003.08.034","volume":"92","author":"Rich S.","year":"2003","unstructured":"Rich S, Shillington A, McLaughlin V. \n          Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension. \n          Am J Cardiol  \n          2003; \n          92\n          (11)\n          : 1366-8.","journal-title":"Am. J. Cardiol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.201705-0943OC","volume":"197","author":"Zamanian R.T.","year":"2018","unstructured":"Zamanian RT, Hedlin H, Greuenwald P, et al. \n          Features and outcomes of methamphetamine-associated pulmonary arterial hypertension. \n          Am J Respir Crit Care Med  \n          2018; \n          197\n          (6)\n          : 788-800.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00104807","volume":"31","author":"Souza R.","year":"2008","unstructured":"Souza R, Humbert M, Sztrymf B, et al. \n          Pulmonary arterial hypertension associated with fenfluramine exposure: Report of 109 cases. \n          Eur Respir J  \n          2008; \n          31\n          (2)\n          : 343-8.","journal-title":"Eur. Respir. J."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"195S","DOI":"10.1378\/chest.114.3_Supplement.195S","volume":"114","author":"Simonneau G.","year":"1998","unstructured":"Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot JL, Herv\u00e9 P. \n          Primary pulmonary hypertension associated with the use of fenfluramine derivatives. \n          Chest  \n          1998; \n          114\n          (3)\n          : 195S-9S.","journal-title":"Chest"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e042673","DOI":"10.1161\/JAHA.125.042673","volume":"14","author":"Uhland C.","year":"2025","unstructured":"Uhland C, Gibbs A, Insel M, Kubba S, Rischard FP. \n          Treatment response and survival in methamphetamine\u2010associated pulmonary arterial hypertension. \n          J Am Heart Assoc  \n          2025; \n          14\n          (21)\n          : e042673.","journal-title":"J. Am. Heart Assoc."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1513\/AnnalsATS.202007-774OC","volume":"18","author":"Kolaitis N.A.","year":"2021","unstructured":"Kolaitis NA, Zamanian RT, de Jesus Perez VA, et al. \n          Clinical differences and outcomes between methamphetamine-associated and idiopathic pulmonary arterial hypertension in the pulmonary hypertension association registry. \n          Ann Am Thorac Soc  \n          2021; \n          18\n          (4)\n          : 613-22.","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e70180","DOI":"10.1111\/echo.70180","volume":"42","author":"O\u2019Neill E.","year":"2025","unstructured":"O\u2019Neill E, Lu DY, Ramakrishna S, et al. \n          Methamphetamine\u2010associated pulmonary arterial hypertension is associated with worse right ventricular function than idiopathic pulmonary arterial hypertension: A matched study. \n          Echocardiography  \n          2025; \n          42\n          (5)\n          : e70180.","journal-title":"Echocardiography"},{"key":"ref11","first-page":"251","volume":"22","author":"Mlczoch J.","year":"1980","unstructured":"Mlczoch J, Probst P, Szeless S, Kaindl F. \n          Primary pulmonary hypertension: Follow-up of patients with and without anorectic drug intake. \n          Cor Vasa  \n          1980; \n          22\n          (4)\n          : 251-7.","journal-title":"Cor Vasa"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jcmg.2014.12.029","volume":"8","author":"Haddad F.","year":"2015","unstructured":"Haddad F, Spruijt OA, Denault AY, et al. \n          Right heart score for predicting outcome in idiopathic, familial, or drug- and toxin-associated pulmonary arterial hypertension. \n          JACC Cardiovasc Imaging  \n          2015; \n          8\n          (6)\n          : 627-38.","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref13","first-page":"111","volume":"27","author":"Loogen F.","year":"1985","unstructured":"Loogen F, Worth H, Schwan G, Goeckenjan G, L\u00f6sse B, Horstkotte D. \n          Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. \n          Cor Vasa  \n          1985; \n          27\n          (2-3)\n          : 111-24.","journal-title":"Cor Vasa"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/bmj.283.6296.881","volume":"283","author":"Douglas J.G.","year":"1981","unstructured":"Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT. \n          Pulmonary hypertension and fenfluramine. \n          BMJ  \n          1981; \n          283\n          (6296)\n          : 881-3.","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1183\/09031936.93.03050606","volume":"3","author":"Pouwels H.M.","year":"1990","unstructured":"Pouwels HM, Smeets JL, Cheriex EC, Wouters EF. \n          Pulmonary hypertension and fenfluramine. \n          Eur Respir J  \n          1990; \n          3\n          (5)\n          : 606-7.","journal-title":"Eur. Respir. J."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","volume":"173","author":"Humbert M.","year":"2006","unstructured":"Humbert M, Sitbon O, Chaouat A, et al. \n          Pulmonary arterial hypertension in France: Results from a national registry. \n          Am J Respir Crit Care Med  \n          2006; \n          173\n          (9)\n          : 1023-30.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10741-017-9612-9","volume":"22","author":"Garg L.","year":"2017","unstructured":"Garg L, Akbar G, Agrawal S, et al. \n          Drug-induced pulmonary arterial hypertension: A review. \n          Heart Fail Rev  \n          2017; \n          22\n          (3)\n          : 289-97.","journal-title":"Heart Fail. Rev."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e029024","DOI":"10.1161\/JAHA.122.029024","volume":"12","author":"Maron B.A.","year":"2023","unstructured":"Maron BA. \n          Revised definition of pulmonary hypertension and approach to management: A clinical primer. \n          J Am Heart Assoc  \n          2023; \n          12\n          (8)\n          : e029024.","journal-title":"J. Am. Heart Assoc."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000564","author":"Jain S.","year":"2023","unstructured":"Jain S, Yingchoncharoen P, Nugent K. \n          Effect of continuous positive airway pressure therapy in patient with obstructive sleep apnea and pulmonary hypertension: A literature review. \n          Cardiol Rev \n          2023.","journal-title":"Cardiol. Rev."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S2213-2600(15)00544-5","volume":"4","author":"Evans J.D.W.","year":"2016","unstructured":"Evans JDW, Girerd B, Montani D, et al. \n          BMPR2 mutations and survival in pulmonary arterial hypertension: An individual participant data meta-analysis. \n          Lancet Respir Med  \n          2016; \n          4\n          (2)\n          : 129-37.","journal-title":"Lancet Respir. Med."}],"container-title":["The Open Respiratory Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openrespiratorymedicinejournal.com\/contents\/volumes\/V20\/e18743064473701\/e18743064473701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrespiratorymedicinejournal.com\/contents\/volumes\/V20\/e18743064473701\/e18743064473701.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrespiratorymedicinejournal.com\/contents\/volumes\/V20\/e18743064473701\/e18743064473701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:32:18Z","timestamp":1776421938000},"score":1,"resource":{"primary":{"URL":"https:\/\/openrespiratorymedicinejournal.com\/VOLUME\/20\/ELOCATOR\/e18743064473701\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,4,17]]}},"URL":"https:\/\/doi.org\/10.2174\/0118743064473701260415041740","relation":{},"ISSN":["1874-3064"],"issn-type":[{"value":"1874-3064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"0000-0002-7092-5784","URL":"0000-0002-7092-5784","order":0,"name":"orcid","label":"ORCID","group":{"name":"identifiers","label":"Identifiers"}},{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e18743064473701"}}